In May 2022, Knight and Helsinn Healthcare SA ("Helsinn") had entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO (netupitant/palonosetron - fosnetupitant /palonosetron) in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV (palonosetron) in Canada. In January 2025, Knight and Helsinn announced that they expanded their existing relationship and entered into an exclusive license, distribution and supply agreement for ONICIT IV (palonosetron) in Mexico, Bra ...